Four Business Models Riding The Silver Tsunami
As baby boomers retire in record numbers, SMBs will need to find new owners or be shut down. New innovative models are ...
Humana Q4 Earnings Review: A Tough Quarter -- And A Rating Downgrade
Humana's 2024 earnings reveal revenue growth but major structural issues impacting profitability. Learn about risks, new ...
Hosted on MSN1d
Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) in Q4 CY2024, with sales flat year on year at $594 million. Its ...
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that ...
What Making America Healthy Again Means For The Nation
In a relatively short time, RFK Jr. has forced America to begin to recognize that the food choices they make have significant ...
Hosted on MSN6d
Bristol-Myers Squibb (NYSE:BMY) Posts Better-Than-Expected Sales In Q4 But Full-Year Sales Guidance Misses Expectations
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced in Q4 CY2024, with sales up 7.5% year on year to $12.34 ...
Pharmaceutical Technology6d
USPTO grants patent to Vistagen’s neuropathic pain treatment
The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.